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The purpose of this randomized trial was to evaluate the efﬁcacy of combination chemoimmunotherapy compared with
chemotherapy alone. A total of 124 patients were randomized to receive intravenous cisplatin (35 mg m
72, days 1–3),
carmustine (150 mg m
72, day 1, cycles 1 and 3 only), dacarbacine (220 mg m
72, days 1–3) and oral tamoxifen (20 mg m
72,
daily) in combination with (n=64) or without (n=60) sequential subcutaneous IL-2 and IFN-a. In those patients who received
sequential immunotherapy, each cycle of chemotherapy was followed by outpatient s.c. IL-2 (10610
6 IU m
72, days 3–5,
week 4; 5610
6 IU m
72, days 1, 3, 5, week 5) and s.c. IFN-a (5610
6 IU m
72, day 1, week 4; days 1, 3, 5, week 5). The
overall response rate of patients treated with the combination of chemotherapy and IL-2/IFN-a was 34.3% with seven
complete responses (10.9%) and 15 partial responses (23.4%). In patients treated with chemotherapy, only, the overall
response rate was 29.9% with eight complete responses (13.3%) and 10 partial responses (16.6%). There was no signiﬁcant
difference in median progression free survival (0 months vs 4 months) and in median overall survival (12 months vs 13
months) for combined chemoimmunotherapy and for chemotherapy, respectively.
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Metastatic melanoma responds poorly to the currently available
chemotherapeutic agents and, until today, no standard treatment
has been established. Most single agent chemotherapeutics provide
only low response rates. Dacarbazine (DTIC), the most active
single agent in the treatment of melanoma, can be expected to yield
a response rate of about 20% (McClay and McClay, 1996). Even
though most trials of combination chemotherapy for the treatment
of metastatic melanoma clearly have not been superior to DTIC
alone, the combination of carmustine (BCNU), DTIC, cisplatin,
and tamoxifen has produced signiﬁcant antitumour responses in
up to 50% of patients (McClay and McClay, 1994; Middleton et
al, 2000; Richards et al, 1992). A further increase in the rate of
objective responses may be achieved by introducing cytokines into
the therapeutic regimens, with interleukin-2 (IL-2) and interferon
alpha (IFN-a) being the most widely acclaimed. Monotherapy with
IL-2 results in up to 29% objective responses (Rosenberg et al,
1994). Different types of interferons have also been intensively
explored (Creagan et al, 1990). While a deﬁned subgroup of
patients has responded, response rates with immunochemothera-
pies have been lower than with the best chemotherapy regimens,
however, sustained responses have been consistently observed
following IL-2 based chemoimmunotherapy.
Recently, several trials have investigated the combination of
various cytotoxic agents with IL-2 and IFN-a. While primarily in
phase II studies several authors claimed a clear advantage of this
chemoimmunotherapy over chemotherapy alone (Legha et al,
1996; Richards et al, 1992), more recently randomized trials raised
doubts about the effectiveness and beneﬁt of this combination
(Johnston et al, 1998; Rosenberg et al, 1999).
We have performed a prospective randomized trial in patients
with metastatic melanoma treated either with a chemotherapy regi-
men of cisplatin, carmustine, dacarbazine, and tamoxifen, or with
the identical chemotherapy followed by outpatient s.c. IL-2 and
s.c. IFN-a.
PATIENTS AND METHODS
Patients
Between May 1995 and May 1999, 124 patients were randomized
and considered evaluable for response (Table 1). Forty-one females
and 83 males were treated either with combined chemoimmuno-
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www.bjcancer.comor chemotherapy alone. Median follow-up of these patients was 12
months (range 0–62 months). Ninety-seven patients had not been
treated with systemic therapy before, 27 patients had received
previous systemic immuno- or chemotherapy treatment.
Criteria for entry into the study were: histologically conﬁrmed
metastatic melanoma; Karnofsky performance status 480%; white
blood cell count 43500 ml
71; platelet count 4100000 ml
71;
haematocrit 430%; serum creatinin and bilirubin 51.5 of the
upper normal limit; age between 18 and 75 years and a life expec-
tancy of 43 months.
This study was approved by the institutional review board of the
Medizinische Hochschule Hannover and by participating centres;
written informed consent was obtained from all patients prior to
entry into the study.
Study design
All patients received a chemotherapy regimen comprising cisplatin
(35 mg m
72, i.v., days 1–3), carmustine (150 mg m
72, i.v., day
1, cycles 1 and 3 only), dacarbacine (220 mg m
72, i.v., days 1–3)
and oral tamoxifen (20 mg m
72, daily) in combination with
(n=64) or without (n=60) subcutaneous IL-2 and IFN-a. In those
patients, who were randomized to receive chemoimmunotherapy,
each cycle of chemotherapy was followed by outpatient immu-
notherapy with combined IL-2 (10610
6 IU m
72, days 3–5, week
4; 5610
6 IU m
72, days 1, 3, 5, week 5) and IFN-a
(5610
6 IU m
72, day 1, week 4; days 1, 3, 5, week 5); randomiza-
tion was performed centrally. Five week treatment cycles were
repeated unless progression of disease occurred. Re-evaluation of
the patients’ tumour status was performed between treatment cycles.
Patients received an average of 2.7 (Arm A, median 2.0; range 1–5)
and 1.9 (Arm B, median 2.0; range 0–4) treatment cycles.
Assessment of response
Response to therapy was evaluated according to World Health
Organization (WHO) criteria with regular re-evaluation intervals
every 8 weeks; all repeated scans were reported to the data center:
complete response – disappearance of all signs of disease for a
minimum of 8 weeks; partial response – 50% or more reduction
in the sum of products of the greatest perpendicular diameters
of measurable lesions, no increase in lesion size and no new lesions;
stable disease – less than a partial response with no disease
progression for at least 8 weeks; progressive disease – 25% or
more increase in sum of products in the longest perpendicular
diameters of measurable lesions or the development of new lesions.
Duration of response was measured from the initial date of
response. Two patients were randomized, but did not receive ther-
apy and were evaluated as progressive disease patients. Treatment
efﬁcacy was assessed on intent-to-treat basis.
Statistical analysis
Survival was measured from start of therapy to date of death or to
the last known date to be alive. The statistical end points in our
analysis were (1) objective response and (2) overall and progression
free survival of patients. The progression free survival after 1 year
was assumed to be 40% (chemoimmunotherapy) and 20%
(chemotherapy), respectively. The intention was to ﬁnd a
chemoimmunotherapy induced progression free survival beneﬁt
over chemotherapy alone at 20% with a probability of 95%
(a=0.05) and a sample power of 1-ß=0.80. Based on this assump-
tion an intended patient accrual of 64 patients per therapy arm was
required in case of a statistically signiﬁcant survival beneﬁt after
combined chemoimmunotherapy. The probability of overall survi-
val was plotted over time according to the method of Kaplan and
Meier. Statistical signiﬁcance was assessed using the Log Rank,
Tarone Ware and the Breslow test; SPSS software was employed.
RESULTS
A total of 124 patients were enrolled in this clinical trial and
randomized to receive combined chemoimmunotherapy (n=64)
or chemotherapy alone (n=60) (Table 1). Patient evaluation was
performed according to the guidelines described above.
Response to therapy was evaluated according to World Health
Organization (WHO) criteria with regular reevaluation intervals
every 8 weeks.
Treatment response
Seven patients (10.9%) treated with chemoimmunotherapy
achieved a complete response and 15 patients (23.4%) had a partial
remission (Table 2). The overall objective response rate of
combined chemoimmunotherapy was 34.3% (median survival 29
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Table 1 Patients’ characteristics
Therapy
a
Characteristics Arm A Arm B All
Entered 64 60 124
Sex
Men 46 37 83
Women 18 23 41
Age
Median 57 57 57
Range 28–72 29–77 28–77
Histology
Cutaneous
Nodular 13 18 31
Amelanotic 1 0 1
Superﬁcial spreading 18 14 32
Acral lentiginous 3 2 5
Uveal 6 5 11
Unknown 14 13 27
Pretreatment
Surgery 53 54 107
Local radiation 6 10 16
Chemotherapy 4 3 7
Immunotherapy; 5 6 11
Chemo/immunotherapy 2 2 4
Others 1 4 5
aArm A (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. IL-2, s.c. IFN-a); Arm B
(i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen).
Table 2 Sites of disease and response of patients receiving DTIC, cispla-
tin, BCNU and tamoxifen followed by immunotherapy with IL-2 and IFN-a
Response
Tumour site
a CR PR SD PD Total
Lymph nodes 5 7 5 21 38
Liver 1 9 4 22 36
Lung 1 8 3 15 27
Local relapse 0 1 1 4 6
Skin/subcutaneous 3 1 0 6 10
Brain 0 0 0 1 1
Bone 0 1 0 3 4
Adrenal 0 2 1 2 5
Spleen 0 2 0 4 6
Other 0 0 1 6 7
Total 7 15 9 33 64
Abbreviations: CR, complete remission; PR, partial remission; SD, stable disease; PD,
progressive disease.
aPatients may have had more than one site.
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months (range 5–62 months). While in complete responders, the
median response duration was 25 months (range 5–62 months),
the median duration of partial responses was 7 months (range
5–19 months). Objective tumour regressions were seen in lymph
nodes (12), liver (10), lung (9), skin (4), bone (1), adrenal (2)
and spleen (2). Nine patients (14.1%) showed disease stabilization
and 33 patients (51.6%) exhibited continuous disease progression
despite therapy.
In the chemotherapy group the overall objective response rate was
29.9% (median survival 24 months; 95% CI, 16, 32) with eight
patients (13.3%) achieving a complete response and 10 patients
(16.6%) a partial remission (Table 3). The median duration of
response ranged from 5 to 47 months (CR, PR, median 15 months).
While in complete responders, the median duration of response
ranged from 5 to 47 months (median 28 months), the median dura-
tion of response in partial responders ranged from 5 to 34 months
(median 7 months), respectively. Objective tumour regressions were
seen in lymph nodes (14), liver (3), lung (9), skin (4) and adrenal (1).
Fourteen patients (23.3%) showed disease stabilization. In 28 patients
(46.7%) progression of disease occurred.
Overall survival
Overall median survival of all patients entered into the study was
13 months (95% CI 10; 16). There was no signiﬁcant difference
in median overall survival for combined chemoimmunotherapy
(12 months) and for chemotherapy (13 months), respectively
(Figure 1). Patients’ sex had also no inﬂuence on median survival
(data not shown). Twenty-ﬁve patients are alive at a median
follow-up of 24 months (range 2–62 months). Two patients
continue to be alive after more than 5 years from chemoimmu-
notherapy. A 3-year survival of 12.96% and 11.42% was achieved
with combined chemoimmunotherapy and with chemotherapy
alone, respectively. For complete responders, median survival has
not been reached at 62 months (range 20–62 months). In contrast,
partial responders and patients with disease stabilization had both a
median survival of 16 months (range 5–40 months and 2–38
months) as opposed to a median survival of 8 months (range
0–40 months) in progressive disease patients (Figure 2).
In the chemoimmunotherapy group, median overall survival of
objective responses was 29 months (range 5–62 months, 95% CI
9, 49), while in the chemotherapy group a median survival of 24
months (range 8–47 months, 95% CI 16, 32) was achieved (data
not shown).
There was a signiﬁcant (P50.0001) difference in overall survival
for all patients with liver metastases with a median survival of 9
months (chemoimmunotherapy) and 8 months (chemotherapy) as
opposed to patients without liver metastases with a median survival
of 20 months (chemoimmunotherapy) and 17 months (chemother-
apy), respectively (Figure 3).
Progression free survival
The progression free survival ranged from 0 to 62 (median 4
months) for all patients entered into the study. There was no
signiﬁcant difference in median progression free survival between
patients treated with chemoimmunotherapy (0 months, range 0–
62 months) or with chemotherapy (4 months, range 0–47 months)
(Figure 4).
The median progression free survival for patients with liver
metastases was 0 months independent of the treatment regimen
as compared to a median progression free survival of 7 months
(range 0–62 months, chemoimmunotherapy) and 5 months (range
0–47 months, chemotherapy) in patients without liver metastases
(data not shown).
Treatment toxicity
Chemotherapy led to signiﬁcant haematotoxicity with WHO grade
IV thrombocytopenia in 25% and leukopenia in approximately
26% of treatment cycles, respectively. Immunotherapy related side
effects included WHO grade III and IV malaise in 21%, anorexia in
21%, chills in 8%, diarrhoea in 5% and fevers in less than 25% of
treatment cycles, respectively (data not shown).
Overall, no life threatening toxicities were observed, and no
toxic deaths occurred. Generally, immunotherapy could be admi-
nistered in the outpatient setting. Chemotherapy required
inpatient stays of 4 days per cycle.
DISCUSSION
In the present prospective randomized trial we reported the
results of 124 patients with progressive metastatic melanoma
who received a combined chemoimmunotherapy (IFN-, IL-2
combined with DTIC, cisplatin, BCNU, and tamoxifen) or a
chemotherapy (DTIC, cisplatin, BCNU, and tamoxifen) alone.
We observed an overall objective response in 34.3% of patients
treated with the combined chemoimmunotherapy which is
comparable with earlier trials achieving response rates between
23% to 64% (Atkins et al, 1994; Atzpodien et al, 1995; Feun
et al, 1995; Hoffmann et al, 1998; Johnston et al, 1998; Legha,
1998; Middleton et al, 2000; Pyrhonen et al, 1992; Rosenberg
et al, 1999; Thompson et al, 1997). Whereas in previous clinical
trials, introducing cytokines in chemotherapeutic regimens
yielded an enhanced efﬁcacy (Atkins et al, 1994; Legha et al,
1996), our results raise doubts concerning the potential beneﬁts
of the presently used dosages of IL-2 and INF-a for therapy of
metastatic melanoma since objective response rates of patients
treated with chemotherapy alone were similar (29.9%) to sequen-
tial chemoimmunotherapy (34.3%).
In addition, in our trials no signiﬁcant difference in survival
time was observed for patients treated with chemoimmunother-
apy (median 12 months) and chemotherapy (median 13
months), respectively, which is also supported by recent results
of other cytokine based therapy regimens (Johnston et al, 1998;
Rosenberg et al, 1999). Although overall survival of objective
responses was slightly increased in the chemoimmunotherapy
group (median 29 months, 95% CI 9, 49) than in the
chemotherapy group (median 24 months, 95% CI 16, 32), the
response duration of patients was shorter after chemoimmu-
notherapy (median 9 months) when compared to
chemotherapy (15 months). In contrast, Legha et al (1997)
reported a signiﬁcantly increased proportion (10%) of long-term
responders after chemoimmunotherapy.
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Table 3 Sites of disease and response of patients receiving DTIC, cispla-
tin, BCNU and tamoxifen
Response
Tumour site
a CR PR SD PD Total
Lymph nodes 5 9 8 17 39
Liver 1 2 4 19 26
Lung 4 5 8 17 34
Local relapse 1 2 2 2 7
Skin/subcutaneous 1 3 4 4 12
Brain 0 0 1 2 3
Bone 0 0 3 3 6
Adrenal 1 0 0 4 5
Spleen 0 0 1 4 5
Other 0 2 2 2 6
Total 8 10 14 28 60
Abbreviations: CR, complete remission; PR, partial remission; SD, stable disease; PD,
progressive disease.
aPatients may have had more than one site.
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1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 2 43 6 4 86 07 2
Months
Arm A vs Arm B
Log Rank P = 0.7904
Breslow P = 0.9313
Tarone P = 0.9697
Arm A
DTIC, Cisplatin, BCNU
Tamoxifen, IL-2, IFN-a
n = 64 patients
Median = 12 months
3-year survival = 12.96%
Arm B
DTIC, Cisplatin
BCNU, Tamoxifen
n = 60 patients
Median = 13 months
3-year survival = 11.42%
No. of patients at risk
Arm A 64 32 17 8 4 2
Arm B 60 31 15 5 – –
P
Figure 1 Overall survival (Kaplan-Meier estimates) of 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen,
s.c. interleukin-2 and s.c. interferon-a) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and p.o. tamoxifen) alone. Survival was measured from start of
therapy.
1.0
0.8
0.6
0.4
0.2
0.0
01 2 2 43 64 86 0 7 2
Months
CR
n = 15 patients
Median not reached
3-year survival = 60.67%
No. of patients at risk
CR 15 15 13 8 4 2
PR 15 18 8 3 0 0
SD 23 11 6 2 – –
PD 61 20 6 2 – –
P
PR
n = 25 patients
Median = 16 months
3-year survival = 20.27%
SD
n = 23 patients
Median = 16 months
3-year survival = 8.85%
PD
n = 61 patients
Median = 8 months
3-year survival = 1.96%
CR vs PR
Log Rank P = 0.0002
Breslow P = 0.0002
Tarone P = 0.0002
PR vs SD
Log Rank P = 0.5499
Breslow P = 0.5617
Tarone P = 0.5679
SD vs PD
Log Rank P = 0.0059
Breslow P = 0.0028
Tarone P = 0.0030
CR
SD
PR PD
Figure 2 Overall survival (Kaplan-Meier estimates) of 124 patients classiﬁed by treatment response. CR=complete remission, PR=partial remission,
SD=stable disease, PD=progressive disease. Survival was measured from start of therapy.
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1.0
0.8
0.6
0.4
0.2
0.0
01 2 2 43 64 86 0 7 2
Months
1 = Arm A, without liver metastases,
DTIC, Cisplatin, BCNU
Tamoxifen, IL-2, IFN-a
n = 28 patients
Median = 20 months
3-year survival = 29.61%
No. of patients at risk
1 = 28 19 12 6 4 2
2 = 35 22 12 4 – –
3 = 36 13 6 3 0 0
4 = 25 10 3 2 – –
P 2 = Arm B, without liver metastases,
DTIC, Cisplatin
BCNU, Tamoxifen
n = 36 patients
Median = 17 months
3-year survival = 15.08%
3 = Arm A, with liver metastases,
DTIC, Cisplatin, BCNU,
Tamoxifen, IL-2, IFN-a
n = 36 patients
Median = 9 months
3-year survival = 7.9%
4 = Arm B, with liver metastases,
DTIC, Cisplatin
BCNU, Tamoxifen
n = 26 patients
Median = 8 months
3-year survival = 4.8%
1
2
3 4
Figure 3 Overall survival (Kaplan-Meier estimates) of 124 patients classiﬁed by risk (liver metastases). Survival was measured from start of therapy.
1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 2 43 6 4 86 07 2
Months
Arm A vs Arm B
Log Rank P = 0.8245
Breslow P = 0.8123
Tarone P = 0.8447
Arm A
DTIC, Cisplatin, BCNU
Tamoxifen, IL-2, IFN-a
n = 64 patients
Median = 0 months
3-year survival = 8.13%
Arm B
DTIC, Cisplatin
BCNU, Tamoxifen
n = 60 patients
Median = 4 months
3-year survival = 10.91%
No. of patients at risk
Arm A 64 11 6 4 3 2
Arm B 60 12 6 5 – –
P
Figure 4 Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-
2 and s.c. interferon-a) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and i.v. tamoxifen) alone. Plots were generated by the Kaplan-Meier method and
progression free survival was measured from start of therapy.
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therapies might be best explained by the following uncontrolled vari-
ables: (A) patient selection and clinical/biological risk; (B) variations
in the rIL-2 based regimen (e.g., reconstitution of drug, route and
dose of administration); and (C) different standards of patient care
(e.g., supportive care upon IL-2 therapy). In fact, previous reports
have repeatedly shown that overall survival is higly risk-dependent
(Hoffmann et al, 1998; Rusthoven et al, 1996). This is conﬁrmed
by our study since we reported that patients with liver metastases
had a signiﬁcantly shorter survival and shorter progression free survi-
val compared to patients without liver metastases. Notably, the
proportion of patients with hepatic metastases varied between 56%
(chemoimmunotherapy) and 43% (chemotherapy alone).
In summary, this prospectively randomized clinical trial showed
no statistically signiﬁcant beneﬁt of IL-2, INF- based combined
chemoimmunotherapy in patients with metastatic melanoma
compared to chemotherapy alone. So far, also no standard was estab-
lished conﬁrming a signiﬁcant survival beneﬁt of polychemotherapy
when compared to DTIC, alone (Chiarion Sileni et al, 2001).
While median duration of objective responses appeared to be
prolonged in patients receiving chemotherapy only, overall survival
analysis yielded few (n=2) long term (448 months) surviving
patients in the chemoimmunotherapy combination, only. Similar
results were reported when comparing dacarbazine/INF- with or
without IL-2. Since cytokines in chemotherapies also alter the toxi-
city proﬁle (Falkson et al, 1998; Johnston et al, 1998; Stark et al,
1998), future clinical trials might focus on new combinations,
different dosages and dose distribution regimens of IL-2 and
INF- to increase both efﬁcacy and tolerability for patients with
metastatic melanoma.
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